Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial
J. Clin. Oncol 2023 Jan 04;[EPub Ahead of Print], MA Dimopoulos, A Oriol, H Nahi, J San-Miguel, NJ Bahlis, SZ Usmani, N Rabin, RZ Orlowski, K Suzuki, T Plesner, SS Yoon, D Ben Yehuda, PG Richardson, H Goldschmidt, D Reece, T Ahmadi, X Qin, W Garvin Mayo, X Gai, J Carey, R Carson, P MoreauFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.